BioCurate
BioCurate is a not-for-profit joint venture of the University of Melbourne and Monash University that funds and advances early-stage biomedical research from these institutions into pre-clinical therapeutic candidates. It offers a Proof of Concept Fund (up to $500,000 per project), due diligence, and global industry linkages to academic researchers in Victoria, Australia.
- Company typePrivate
- Founded2019
- HeadquartersVictoria, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What BioCurate does
BioCurate is an Australian not-for-profit joint venture, formed in 2019 by the University of Melbourne and Monash University with the support of the Victorian State Government, whose mission is to identify promising biomedical research discoveries from these institutions and advance them into high-quality pre-clinical candidates for novel human therapeutics. It is operationally independent, headquartered in Carlton, Melbourne, and staffed by a small team (1-10 employees) of senior drug development professionals whose collective track record includes more than 170 years of biotech/pharma experience, 13 INDs, 30 therapeutics currently in the clinic, and more than $2.4 billion in cumulative deal value.
BioCurate's core offering is a project evaluation and due diligence service combined with a Proof of Concept Fund that provides up to $500,000 per project to generate industry-standard experimental validation and de-risk early-stage therapeutic assets. Its active portfolio comprises four Portfolio projects and nine Proof of Concept projects spanning oncology, neurological disease, cardiovascular disease, and other indications. The organisation also publishes an extensive library of educational fact sheets covering IP strategy, target validation, antibody validation, FDA guidance, Target Product Profile construction, and valuation frameworks, and participates in industry events such as BIO International Convention and the Business of Regenerative Medicine Asia Pacific Symposium.
BioCurate does not earn commercial revenue in the traditional sense; it is funded by its founding universities and the Victorian State Government, supplemented by matching co-funding from the MTPConnect Biomedical Translation Bridge Program (up to $1 million per project). Its go-to-market is community-led and researcher-focused, engaging Monash and University of Melbourne investigators through information sessions, pipeline reviews, and a formal BioCurate Opportunity Assessment process, with the objective of licensing or spinning out industry-ready assets into the global biopharmaceutical pipeline.
BioCurate firmographics
Firmographics- Name
- BioCurate
- Legal name
- BioCurate
- Website
- https://biocurate.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BioCurate is a not-for-profit joint venture of the University of Melbourne and Monash University that funds and advances early-stage biomedical research from these institutions into pre-clinical therapeutic candidates. It offers a Proof of Concept Fund (up to $500,000 per project), due diligence, and global industry linkages to academic researchers in Victoria, Australia.
- Ownership category
- akta.pro rank
BioCurate industry classification
Industry- Product category
- Biotechnology Translation Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Translational Medicine & Biomarkers (HLAIALAF)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)
Keywords
Where BioCurate is headquartered
LocationHeadquarters
- HQ city
- Victoria
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
BioCurate business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Not-for-profit translation entity: BioCurate is a purpose-built, not-for-profit company designed to help achieve impact from university research. They provide funding, expertise, and networks to translate discoveries into industry-ready assets. They do not generate revenue in the traditional sense but are operationally independent with support from founding universities and Victorian Government.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
BioCurate product offering
Product offeringCore offering
BioCurate identifies promising biomedical research discoveries from Monash University and the University of Melbourne and advances them into high-quality pre-clinical candidates for novel human therapeutics. The company provides funding (Proof of Concept Fund up to $500,000), expert evaluation services, and access to global biopharmaceutical networks to translate early-stage academic discoveries into industry-ready therapeutic assets.
Product overview
BioCurate is a not-for-profit joint venture between Monash University and the University of Melbourne, supported by the Victorian State Government, that provides translational drug development services. The company offers a Proof of Concept Fund (up to $500,000 for early-stage validation), manages a portfolio of therapeutic projects spanning oncology and neurological diseases, and provides educational resources including fact sheets on IP strategy, target validation, unmet medical need, FDA guidance, and drug development best practices. BioCurate's core offering is its project evaluation and due diligence services that bridge academia and industry.
Differentiator
Problem solved
Functional benefit
Products and services
- Proof of Concept Fund A funding program that supports early-stage therapeutic projects with up to $500,000 to provide industry-standard experimental validation, generate compelling data, de-risk projects, and propel them to the next value inflection point. Targeted at researchers from Monash University, University of Melbourne, and affiliated Medical Research Institutes.
- Project Evaluation and Due Diligence Services Formal, rigorous process for project review and investment decision-making including initial screening, investigator meetings, due diligence, and Investment Committee review for therapeutic development projects. Targeted at academic researchers submitting therapeutic candidates for advancement.
Quantifiable outcome
- More than 170 years of combined biotech/pharma industry experience
- +3 more outcomes
Companies that use BioCurate
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
BioCurate technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
BioCurate partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- MTPConnectcoreMTPConnect operates the Biomedical Translation Bridge (BTB) Program in partnership with BioCurate, UniQuest, Medical Device Partnering Program, and Bridge/BridgeTech programs. The BTB Program provides up to $1 million in matching funding to nurture translation of new therapies, technologies, and medical devices through proof of concept.
- UniQuestcoreUniQuest is a partner in the Biomedical Translation Bridge (BTB) Program operated by MTPConnect, working with BioCurate and other partners to support translation of therapeutic discoveries.
- Medical Device Partnering ProgramcorePart of of the BTB Program ecosystem supporting translation of medical technologies alongside therapeutics.
- CCRM AustraliaminorCCRM Australia co-hosted the Business of Regenerative Medicine Asia Pacific Symposium with NSW Stem Cell Network. BioCurate CEO presented at this event focused on regenerative medicine translation.
- NSW Stem Cell NetworkminorCo-host of Business of Regenerative Medicine Asia Pacific Symposium with CCRM Australia, bringing together organizations in the regenerative medicine field.
- Monash UniversitycoreFounding partner of BioCurate joint venture. Contributes research discoveries and academic expertise to the translation partnership.
- University of MelbournecoreFounding partner of BioCurate joint venture. Contributes research discoveries and academic expertise to the translation partnership.
- Global biopharmaceutical companiescoreBioCurate has developed linkages with key global biopharmaceutical companies, providing valuable advice and insight to guide research and give projects the best opportunity to progress in the translation process.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
BioCurate competitors and assessment
Company assessmentOthers
- Exopharm: Australian biotech spun out of Monash University and a former employer of BioCurate's Head of Drug Development, Chacko Joseph. It illustrates the type of spin-out entity that BioCurate's translation model is designed to generate and support.
- Therapeutic Innovation Australia (TIA): National infrastructure provider supporting translational research capabilities across Australia. It is an enabler of the same translational ecosystem BioCurate operates in, rather than a direct competitor, but provides comparable services (capability access, project support) to overlapping researcher segments.
Regional players
- Medical Device Partnering Program (MDPP): Flinders University-based program that helps Australian researchers and clinicians translate medical device concepts. It is a co-partner in the BTB Program with BioCurate and UniQuest and operates a comparable academia-industry bridging model in the medical device niche.
- ANDHealth: Australian national digital health commercialization organization. Comparable in mission (bridging research and commercial outcomes in health) but specialized in digital health rather than therapeutics, making it an adjacent rather than direct peer.
Direct peers
- UniQuest: University of Queensland's main commercialization and translation entity. Operates the same academia-to-industry bridge model as BioCurate and is a co-partner in MTPConnect's BTB Program, making it the closest direct functional peer in Australia.
- Queensland Emory Drug Discovery Initiative (QEDDI): Drug discovery and translation initiative embedded in Queensland Brain Institute at the University of Queensland. Directly comparable as a university-based translational drug discovery entity and is explicitly cited in the background of BioCurate's Director of Small Molecule Therapeutics.
- CCRM Australia: Australian node of the Centre for Commercialization of Regenerative Medicine, focused on translating cell and gene therapies and regenerative medicine. Co-hosted events with BioCurate and shares a similar translational mandate for early-stage biomedical research in Australia.
- Australian Translational Medicinal Chemistry Facility (ATMCF): Translational medicinal chemistry capability at Monash University focused on early-stage drug discovery. Dr Raphael Rahmani, BioCurate's Director of Small Molecule Therapeutics, previously worked at ATMCF, illustrating direct institutional overlap with BioCurate's small molecule work.
Broad incumbents
- MTPConnect: Australian Government-funded Industry Growth Centre for the medical technology, biotechnology, and pharmaceutical sector. Operates the Biomedical Translation Bridge Program with BioCurate and UniQuest, making it a partner and a broader, well-funded peer in the same translation ecosystem.
- Brandon BioCatalyst: Australia's largest life sciences venture fund, managing the Medical Research Commercialisation Fund. It sits one step downstream of BioCurate as a likely future investor or acquirer of BioCurate-validated spin-outs, and competes for the same translational deal flow at the funding stage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
BioCurate social profiles
Digital presenceBioCurate financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioCurate leadership team
Management profileNumber of profiles
Profiles9 records
BioCurate funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioCurate M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioCurate
What does BioCurate do?
BioCurate identifies promising biomedical research discoveries from Monash University and the University of Melbourne and advances them into high-quality pre-clinical candidates for novel human therapeutics. The company provides funding (Proof of Concept Fund up to $500,000), expert evaluation services, and access to global biopharmaceutical networks to translate early-stage academic discoveries into industry-ready therapeutic assets.
Is BioCurate a public or private company?
BioCurate is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was BioCurate founded?
BioCurate was founded in 2019. It employs 1 to 10 people.
Where is BioCurate based?
BioCurate is headquartered in Victoria, United Kingdom, in the Europe region.
How does BioCurate make money?
One revenue line is on record: not-for-profit translation entity.
Who are BioCurate's main competitors?
Others on record are Exopharm and Therapeutic Innovation Australia (TIA). Regional players are Medical Device Partnering Program (MDPP) and ANDHealth. Direct peers are UniQuest, Queensland Emory Drug Discovery Initiative (QEDDI), CCRM Australia and Australian Translational Medicinal Chemistry Facility (ATMCF). Broad incumbents are MTPConnect and Brandon BioCatalyst.
Does BioCurate have an API?
No public API is recorded for BioCurate.
What industry is BioCurate in?
BioCurate's product category is Biotechnology Translation Services. Its primary akta.pro industry code is HLAIALAF, Translational Medicine & Biomarkers, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.